KKKatharina A. Kierner

Katharina A. Kierner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katharina A. Kierner has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Polypharmacy in the terminal stage of cancer

    by Katharina A. Kierner, Dietmar Weixler, Eva K. Masel, Verena Gartner, Herbert H. Watzke

    This study aims to determine the numbers of patients with advanced cancer receiving polypharmacy at the end of their lives and analyze differences in drug prescription at a general oncology ward and a dedicated palliative care ward. A retrospective single-center cohort study at a university hospital with a large cancer center was conducted. The charts of 100 patients who had died because of advanced cancer were reviewed; data concerning sociodemographic variables and medications were collected at four predefined time points (9, 6, 3, 0 days before death). Nine days before death, polypharmacy was registered in 95 % of patients; they had prescriptions for 11 (9–13) different medications per day (median, IQR). Although this number dropped significantly, on the last day as many as 61 % of the patients were still taking more than 4 drugs (median 6.5, IQR 4–9). No significant difference was noted between the oncology ward and the palliative care ward. Polypharmacy was largely dependent on the patients’ ECOG performance status as well as the type of ward, the number of days before death, and age. It was not influenced by gender, the duration of hospital stays, and the devices facilitating drug administration. The medications fulfilled the requirements of palliative care in the majority of patients; 90 % received treatment for pain and anxiety. Patients treated at the palliative ward received more opioids and psychoactive drugs while those at the oncology ward received more anti-cancer drugs and fluids. Polypharmacy still is a problem in the large majority of patients with terminal cancer. Further studies should be focused on the patients’ quality of life, drug interactions, and adverse events.


  • Reversible delirium in an advanced cancer patient

    by Katharina A. Kierner, Christian Jagsch, Herbert H. Watzke

    Delirium ist in der Palliativmedizin ein weit verbreitetes und stark belastendes Symptom, dessen Ursachen und Entstehung sind multifaktoriell sind. Studien belegen, dass ein Zusammenspielen bestimmter Auslöser die Entstehung eines Deliriums begünstigen kann. Manche dieser Auslöser sind reversibel. Dieser Fallbericht präsentiert ein reversibles Delirium bei einer Patientin mit fortgeschrittener Krebserkrankung. Des Weiteren findet sich eine Liste möglicher, reversibler medikamentöser Ursachen für ein Delirium, welche vor allem bei älteren Patienten hilfreich sein kann.


  • Attitudes of patients with malignancies towards completion of advance directives

    by Katharina A. Kierner, Birgit Hladschik-Kermer, Verena Gartner, Herbert H. Watzke

    The purpose of advance directives (AD) is to preserve the patient's autonomy at the end of his/her life. In a cohort study, we investigated attitudes towards AD in hospitalized patients with malignant disease. All patients were informed about the basic features of AD in a standardized manner by a single independent physician. One hundred and eight (39 women, 69 men; mean age 56.6 ± 14.9 years) of 140 invited patients completed the study. Five percent of patients (5/108) already had an AD; 85% (92/108) did not wish to issue an AD. “Full confidence in physicians” (22%) and “not important for me at the moment” (15%) were the most frequently stated reasons for not issuing an AD. Only 10% (11/108) of patients decided to complete an AD. Their decision was not related to a specific diagnosis or a number of socio-demographic variables that were studied. Patients who decided in favor of an AD had significantly higher Hospital Anxiety and Depression Scale (HADS-D) score than those who decided against it (HADS-D, 8.3 ± 5.0 vs.5.8 ± 4.1, p = 0.035). The patients' HADS depression score was negatively associated with their Karnofsky index (r = −0.232, p = 0.017). Our data reveal a scarce demand for AD in our population of hospitalized cancer patients. Patients who wanted to issue an AD had a high HADS-D, which is associated with a low performance status.